Who
Brian Lian
President & CEO
Company insider
Files Form 4 as: President & CEO, Viking Therapeutics; Director, Seelos Therapeutics.
In numbers
- Trades disclosed
- 142
- Buys
- 0
- Sells
- 20
- Bought
- $0
- Sold
- $87.3M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 May 2015
- Last trade
- 29 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.9M148,517 at $33.32 | filing |
| 29 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.9M148,517 at $33.32 | filing |
| 28 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —221,667 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —221,667 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.3M132,454 at $32.29 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M53,279 at $33.38 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M41,276 at $34.22 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $224K6,400 at $35.07 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $4.3M132,454 at $32.29 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M53,279 at $33.38 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M41,276 at $34.22 | filing |
| 5 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $224K6,400 at $35.07 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —78,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —224,080 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —176,300 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —176,300 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —78,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —224,080 at $0.00 | filing |
| 28 Oct 2025filed 28 Oct 2025 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M38,989 at $35.01 | filing |
| 27 Oct 2025filed 28 Oct 2025 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —70,084 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Brian Lian; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.